Viking Thera (VKTX)
$64.91
1.56 (2.35%)
VKTX Stock Quote Delayed 30 Minutes
Top 5 Stocks for 2024
INSIDE: Investing legend Louis Navellier reveals his Top 5 Stocks for 2024 — FREE!
Download His Free Report Here:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
6.46B
PE Ratio
-70.55
EPS
-0.92
Volume (Avg. Vol.)
1.85M
Day's Range
$64.50 - $66.25
52-Week Range
$8.28 - $99.41
Dividend & Yield
N/A (N/A)
VKTX Stock Predictions, Articles, and Viking Thera News
Why Is Viking Therapeutics (VKTX) Stock Up 24% Today?
Viking Therapeutics stock is rising higher on Tuesday as investors in VNKTX shares react to positive Phase 1 clinical trial results.
Why Is Viking Therapeutics (VKTX) Stock Up 96% Today?
Viking Therapeutics stock is up on Tuesday with heavy trading of VKTX shares after the company reported positive Phase 2 trial results!
3 Biotech Stocks to Turn $10,000 Into $1 Million: January 2024
Biotech stocks are some of the most exciting opportunities on the market. Find the right ones with catalysts, and you could make a fortune.
Why Is Viking Therapeutics (VKTX) Stock Moving Today?
Viking Therapeutics stock is on the move Wednesday as investors react to results from the company's latest clinical trial!
The 3 Most Undervalued Biotech Stocks to Buy Now: June 2023
If you dig deep enough, you’ll find some undervalued biotech stocks with substantial catalysts straight ahead.
